Table 2.
Baseline characteristics and results of the studies included in our review
| Author, Year | Study duration, months | Disease arms | Patients switched to SB4, n (%) | Female, n (%) | Age, years | Etanercept duration before switching to SB4, years | Concomitant MTX, n (%) | On other bDMARDs before Etanercept, n (%) | DAS- 28 before switching to SB4 | BASDAI before switching to SB4 | Patients failed on SB4, n (%) | Reasons of failure on SB4 | Patients switched to another bDMARD | Patients switched back to Etanercept | Patients stayed on Etanercept after switching back |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glintborg 2018 (6) | 12 | RA | 933 (58%) | 689 (74%) | 61 (49 to 70) | NR | 556 (60%) | 442 (47%) | 1.9 (1.3 to 2.8) | NA | 194 (21%) | LOE (46%), AEs (26%), other reasons (18%) | 104/299 (35%) | 120/299 (40%) | 104/120 (87%) |
| AxSpA | 337 (20,8%) | 115 (34%) | 48 (39 to 57) | NR | 51 (15%) | 214 (64%) | NA | 3.3 (1.5 to 5.2) | 52 (15%) | ||||||
| PsA | 351 (22%) | 160 (46%) | 52 (43 to 61) | NR | 168 (48%) | 170 (48%) | NA | 1.8 (1.1 to 2.4) | 53 (15%) | ||||||
| Tweehuysen 2018 (7) | 6 | RA | 433 (69%) | 341 (55%) | 57 | 3 (2 to 6) | NR | NR | 1.9 (1.5 to 2.6)* | NA | 60 (10%) | LOE (43%), AEs (47%), other reasons (10%) | 32/60 (53%) | 17/60 (28%) | NR |
| AxSpA | 64 (10%) | 3.1 (1.8 to 5.4) | |||||||||||||
| PsA | 128 (21%) | NA | |||||||||||||
| Alkoly 2018 (14) | 6 | RA | 87 (55%) | 70 (80.5%) | 62 | 1.3 (0.8 to 2.2) | NR | 6 (6.9%) | 2.82 | NA | 14 (8.9%) | LOE (50%), AEs (50%) | 0 | 14/14 (100%) | 14/14 (100%) |
| AxSpA | 41 (26%) | 7 (17%) | 42 | 1 (0.4 to 1.6) | 3 (7.3%) | NA | 3.27 | ||||||||
| PsA | 30 (19%) | 12 (40%) | 55 | 2.1 (1.6 to 2.1) | 1 (3.3%) | NA | NA | ||||||||
| Dybal 2017 (15) | NR | RA | 38 (100%) | NR | NR | NR | NR | NR | 3.08 | NA | 6 (16%) | LOE (67%), AEs (33%) | 0 | 5/6 (83%) | NR |
| AxSpA | 0 | NR | |||||||||||||
| PsA | 0 | NR | |||||||||||||
| Krueger 2018 (8) | 3 | RA | 163 (64%) | 112 (69%) | 60.8 (54 to 69) | NR | NR | NR | 2.0 | NA | NR | NR | NR | NR | NR |
| AxSpA | 92 (36%) | 28 (30.4%) | 50.7 (40 to 61) | NA | 3.0 | ||||||||||
| PsA | 0 | NA | NA | NA | NA | ||||||||||
| Lee 2018 (9) | 8 | RA | 56 (100%) | NR | NR | NR | NR | NR | NR | NR | 9 (16%) | LOE (89%), AEs (11%) | 7/9 (78%) | 2/9 (22%) | NR |
| AxSpA | |||||||||||||||
| PsA | |||||||||||||||
| Ma 2018 (10) | 6 | RA | 32 (64%) | 23 (72%) | 60 | 6 | NR | NR | NR | NR | 8 (16%) | LOE (40%), AEs (50%), other reasons (10%) | NR | NR | NR |
| AxSpA | 15 (30%) | 1 (7%) | |||||||||||||
| PsA | 3 (6%) | NR | |||||||||||||
| Rabbits 2017 (11) | NR | RA | 44 (100%) | NR | NR | NR | NR | NR | NR | NR | 8 (18%) | LOE (63%), infection or planned surgery (37%) | NR | NR | NR |
| AxSpA | |||||||||||||||
| PsA | |||||||||||||||
| Rajamani 2018 (12) | NR | RA | 120 (100%) | NR | NR | 9.2 | 96 (80%) | 15 (13%) | NR | NR | 18 (15%) | LOE (60%), AEs (40%) | NR | 9/18 (50%) | NR |
| AxSpA | |||||||||||||||
| PsA | |||||||||||||||
| Smith 2018 (13) | NR | RA | 217 (100%) | NR | NR | NR | NR | NR | NR | NR | 10 (4.6%) | LOE (40%), AEs (50%), missing data (10%) | 0 | 10/10 (100%) | 10/10 (100%) |
| AxSpA | |||||||||||||||
| PsA |
Numbers are medians (interquartile ranges).
*
for both RA and PsA
MTX= Methotrexate, bDMARDs= biological DMARDs, RA= rheumatoid arthritis, PsA= Psoriatic arthritis, AxSpA= axial Spondyloarthropathy, LOE= Loss of effect, AEs= adverse events, NR= Non Reported, NA= Non Applicable,